Oncolytics is focused on obtaining regulatory approval for pelareorep for metastatic breast cancer, an indication with continued and considerable unmet need in third line therapy. Based on very compelling data, Oncolytics believes that advancing pelareorep through late-stage clinical testing, submission and registration in this indication presents the highest chance of success with the greatest commercial opportunity. Source
No articles found.
Evelo develops and sells electric bicycles using a direct-to-consumer distribution...
Evelo develops and sells electric bicycles usin...
BioCryst Pharmaceuticals discovers novel, oral small-molecule medicines that treat...
BioCryst Pharmaceuticals discovers novel, oral ...
Predictive Oncology is a clinical and translational data pipeline and AI-driven pl...
Predictive Oncology is a clinical and translati...
Galmed is a clinical-stage biopharmaceutical company focused on the development of...
Galmed is a clinical-stage biopharmaceutical co...
Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and d...
Cocrystal Pharma, Inc. is a clinical stage biot...
We are a clinical stage biopharmaceutical company focused on harnessing powerful b...
We are a clinical stage biopharmaceutical compa...
Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-bas...
Genomic Health, Inc. (NASDAQ: GHDX) is the worl...
Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) develops proprietary cell therapie...
Cellular Biomedicine Group, Inc. (NASDAQ: CBMG)...
Alpine is a development-stage specialty pharmaceutical company focused on discover...
Alpine is a development-stage specialty pharmac...
Join the National Investor Network and get the latest information with your interests in mind.